Current Report Filing (8-k)
04 October 2021 - 10:01PM
Edgar (US Regulatory)
0000715446
false
0000715446
2021-10-01
2021-10-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or Section 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 1, 2021
ANIXA
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-37492
|
|
11-2622630
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
3150
Almaden Expressway, Suite 250
San
Jose, CA
|
|
95118
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (408) 708-9808
(Former
name or former address, if changed since last report)
|
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under
any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.01 per share
|
|
ANIX
|
|
The
NASDAQ Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On
October 1, 2021, patient recruitment commenced for the initial clinical trial of the preventative breast cancer vaccine being developed
by Cleveland Clinic, the U.S. Department of Defense and Anixa Biosciences, Inc. The study titled, “Phase I Trial of Adjuvant Therapy
With an Alpha-lactalbumin Vaccine in Patients With Non-Metastatic Triple-Negative Breast Cancer at High Risk of Recurrence” is
being performed at Cleveland Clinic and is an open-label, dose-escalation trial in which participants will be treated with successively
higher doses of the vaccine. It is estimated that 18-24 participants will be treated in this trial and the trial is estimated to take
approximately one year to complete. More details regarding the trial can be found at https://www.clinicaltrials.gov/ct2/show/NCT04674306?recrs=b&cond=Breast+Cancer&cntry=US&state=US%3AOH&draw=2.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated:
October 4, 2021
|
ANIXA
BIOSCIENCES, INC.
|
|
|
|
|
By:
|
/s/
Amit Kumar
|
|
Name:
|
Dr.
Amit Kumar
|
|
Title:
|
President
and Chief Executive Officer
|
Anixa Biosciences (NASDAQ:ANIX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Anixa Biosciences (NASDAQ:ANIX)
Historical Stock Chart
From Mar 2023 to Mar 2024